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Abstract
Companion dogs housed in animal shelters are subject to a great number of
uncontrollable and unalterable stressors. To combat these stressors and the associated
immunosuppression that creates high contagious illness rates in sheltered dogs, a large open
admission municipal animal shelter in New York City introduced trazodone hydrochloride as an
anxiolytic to transitional stress. This pilot study had additional goals of reducing length of stay
and increasing live outcome rates. Dogs were given low doses of trazodone at intake (5 mg/kg),
one to two doses within 48 hours of arrival, and illness rates calculated for the months of
November and December 2018 at the shelter’s Brooklyn and Manhattan Care Center locations.
These months were compared to the same months in 2017 and 2016, serving as a pre-trazodone
baseline, using Pearson chi-square and independent samples t-tests. A statistically significant
decrease was found between baseline 2016/2017 and trazodone pilot 2018, ꭓ2, (1, N = 1774) =
19.3, p < .000. Illness rate dropped from 41% in the baseline to 29% with trazodone. A
statistically significant decrease in length of stay was found for 2018 (M = 7.44, SD = .25),
t(1772) = 2.75, p = .006, compared to the 2016/2017 baseline (M = 10.48, SD = 1.22). Moreover,
a significant difference was observed in adoption rates between 2016/2017 and 2018, ꭓ2, (1, N =
1774) = 18.7, p < .000, wherein average adoption rate increased from 30.5% in 2016/2017 to
42% in 2018. While correlational, the preliminary results of this study suggest that trazodone
may be effective in decreasing transitional stress in dogs in a shelter setting and, thereby,
decreasing illness rates and increasing adoption rates.
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Domestic dogs have been humans’ companions for thousands of years (Bradshaw, 2011),
yet they have been historically underrepresented in scientific literature. There has been a recent
increase in studies focusing on dog cognition and behavior but overall, very little consideration
has been given from a welfare perspective (Beerda, Schilder, van Hooff, de Vries, & Mol, 1998;
Hilby, Rooney, & Bradshaw, 2006). One reason for this may be that welfare is exceptionally
difficult to study in a controlled setting, particularly in an animal shelter. Shelters are typically
overpopulated, understaffed, and stretched for resources. Hours are limited and the
overwhelming concern at all times is the welfare of the resident animals; ironically setting aside
time to study welfare diminishes time that could be spent providing enrichment and working
hands-on to improve individuals’ quality of life. While improvements regarding the welfare of
confined animals have been made during recent decades (Fraser, 2008), it is essential to evaluate
interventions in real-world situations, within the hectic, perpetually over- or under-stimulated
shelter environment.
Literature Review
A 2016 survey by the American Society for the Prevention of Cruelty to Animals found
that about 4 million dogs enter a system of approximately 13,000 shelters nationwide
(Protopopova & Gunter, 2017). On average, across the country, these shelters have a collective
euthanasia rate of 30% (Gunter, Barber, & Wynne, 2016; Protopopova & Gunter, 2017). Efforts
are being made to decrease euthanasia rates nationally through adoption promotions, focus on
surrender prevention, and improving housing, care, and welfare in shelters. High stress levels in
shelters can increase illness levels and negatively impact behavior, both of which increase the
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risk of euthanasia. Thus, finding a way to reduce these stress levels is essential as shelters look to
decrease euthanasia rates and increase placement rates.
Animal shelters are known to cause distress for all pets, even the most well-adjusted, due
to the myriad new and typically uncomfortable situations they experience. Anxiety, phobias,
heightened arousal, and distress are among the most commonly-reported behavior issues for
dogs, and those are all exacerbated in a shelter setting (Gruen & Sherman, 2008). Anxious
temperaments in combination with a stressful environment can lead to additional medical issues,
including chronic idiopathic large-bowel disease (Hekman, Karas, & Sharp, 2014). Conflicts,
stress, and frustration caused by the physical and social environment can lead to undesirable
behaviors and stereotypies in the shelter, decreasing the likelihood of adoption (Hennessy, 2013;
Kuhne, Hossler, & Struwe, 2014; Shiverdecker, Schiml, & Hennessy, 2013).
Because of this, animal shelters are faced with constant welfare challenges as dogs
experience a jarring loss of control over their situations (Hennessy, 2013; Shiverdecker et al.,
2013). Dogs are separated from their attachment figures (familiar human and nonhuman animals)
(Hennessy, Davis, Williams, Mellott, & Douglas, 1997; Hennessy, 2013; Protopopova, 2016;
Shiverdecker et al., 2013). They experience severe social isolation, often housed in individual
kennels with limited interaction (Beerda, Schilder, van Hooff, de Vries, & Mol, 1999b; Coppola,
Grandin, & Enns, 2006; Hennessy et al., 1997; Hennessy, 2013; Protopopova, 2016; Wells,
2004). In addition to social isolation, dogs experience radical spatial restriction. Confined to
small areas, their movement is limited and their new living spaces foreign and often austere
(Beerda et al., 1999b; Protopopova, 2016; Shiverdecker et al., 2013). Social and spatial
restriction has been found to change behavior (heightened excitability, increased aggressive
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behaviors, withdrawal, lethargy) and to increase cortisol levels (Beerda et al., 1999b; Wells,
2004). Their routines are disrupted, and housetrained dogs are suddenly left with no alternative
but to eliminate in their living areas (Hennessy, 2013). Many facets of their new environment are
novel and unpredictable (Coppola et al., 2006; Hennessy et al., 1997; Hennessy, 2013;
Shiverdecker et al., 2013). Noises and odors in the shelter are persistent, uncontrollable, and
often threatening (Hennessy, 2013; Shiverdecker et al., 2013). All of these factors contribute to
diminished welfare for dogs in a shelter environment (Beerda, Schilder, van Hooff, & de Vries,
1997; Protopopova, 2016).
The stressful shelter environment means dogs typically need time to adjust to their new
surroundings in order to feel comfortable enough to behave in their normal manner (Bollen &
Horowitz, 2008). However, shelter staff are tasked with making quick decisions about placement
options, suitability for adoption, and medical conditions, sometimes with just a single interaction
and long before there is an opportunity to get to know a dog’s personality, temperament, and full
behavioral repertoire. This situation is intensified in open admission shelters (typically municipal
or animal control facilities), which must accept all animals regardless of available space,
behavior, or medical concerns. For dogs brought into these shelters, there is additional urgency
to limit length of stay both due to high daily intake numbers and in order to minimize
environmental stress. This can be in conflict with allowing each individual dog sufficient
adjustment time. Dogs and their shelter caretakers are also under pressure to make connections
with potential adopters; however, individual housing and other shelter stressors can encourage
behaviors adopters find undesirable, like sitting at the back of the kennel (Wells, 2004), barking,
and disengaging. Adopters, on the contrary, are looking for dogs who are quiet, alert, and at the
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front of the kennel (Wells, 2004). This pressure and conflict challenges both the welfare of the
resident animals and the humans attending to them.
As shelters are rife with uncontrollable stressors upon a dog’s arrival, dogs in animal
shelters and in veterinary hospitals show behavioral and psychological signs of both acute and
chronic psychogenic stress as a result of unpredictability, novelty, confinement, isolation, and
invasive procedures (Gilbert-Gregory, Stull, Rice, & Herron, 2016; Hennessy, 2013). Therefore,
one way to begin to combat the welfare challenges is to address animal stress within the shelter
environment. Stress represents a sequence of events in which a stimulus causes a stress
perception reaction in the brain. When triggered, the body’s sympathetic (fight-or-flight)
response and/or the hypothalamic-pituitary-adrenal (HPA) system is activated (Dhabhar, 2009;
Glaser & Kiecolt-Glaser, 2005). The body enters a distressed state when homeostasis cannot be
restored. This sequence has been found to have adverse effect(s) on health, specifically, physical
and mental suffering (Hekman et al., 2014), as it represents a physical or psychological challenge
to the body’s homeostasis (Dhabhar, 2009; Hekman et al., 2014). Chronic stress can lead to a
dysregulation of the HPA system and suppression of the immune system (Dhabhar, 2009;
Hennessy, 2013; Shiverdecker et al., 2013). Psychogenic and physical stressors abound in a
shelter setting: novelty, routine disruption, unpredictability, and loss of control (Hennessy et al.,
1997; Hennessy, Williams, Miller, Douglas, & Voith, 1998; Hennessy, 2013; Protopopova,
2016). Psychogenic stress is recognized to negatively impact cardiovascular function in humans
and in laboratory animals, while acute social stress has been found to elicit atrial fibrillation in
humans and increase T-wave alternans (a sign of electrical instability) in dogs (Hekman, et al.,
2014; Kovach, Nearing, & Verrier, 2001). The stress response increases susceptibility to and
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severity of infection while decreasing vaccine immune response and slowing wound healing
(Glaser & Kiecolt-Glaser, 2005). This response can also reactivate latent herpesvirus, cause
gastrointestinal distress, and amplify production of pro-inflammatory cytokines associated with
multiple age-related illnesses (Dhabhar, 2009; Glaser & Kiecolt-Glaser, 2005; Hekman et al.,
2014).
Measuring animal welfare, specifically stress, is particularly challenging. No single
parameter has yet been found to accurately gauge wellbeing (Hilby et al., 2006). Therefore,
research evaluating shelter animal welfare has utilized both behavioral and physiological
methods. Behavioral measures include those thought to be associated with anxiety, such as
pacing and other locomotion, vocalization, fleeing, panting, lip licking, and shaking (GilbertGregory et al., 2016). Physiologic measures include cortisol (plasma, salivary, and urinary),
typically as a reflection of HPA axis hormones; salivary immunoglobulin A; neutrophil-tolymphocyte ratio; and heart rate variability (Gilbert-Gregory et al., 2016; Hennessy, 2013).
While neither measure is without its limitations, the findings from both behavioral and
physiologic assessments suggest that intervention in the first few days within the new shelter
environment is critical for a dog’s success in a shelter (Hennessy et al., 1997).
Behavioral measures can be problematic as behaviors are non-specific and represent an
indirect marker of distress (Hekman et al., 2014). In a shelter setting, where subjects have limited
known history, behavioral measures can be unreliable as no behavioral baseline has been
established for individual dogs. In situations where history is reported, the reports are subjective
based on the individual making the observations. Thus, changes in behavior seen in the shelter
may appear more subtle or magnified, and assessments may include some amount of guesswork.
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Behavior in a shelter setting is notoriously capricious when compared to behavior in a stable,
comfortable environment (Bollen & Horowitz, 2008; Haverbeke, Pluijmakers, & Diederich,
2015; Patronek & Bradley, 2016). Behavioral responses to stress can vary between dogs, and can
be difficult for humans to interpret, suggesting that additional measures must be used to provide
sufficient information (Beerda et al., 1998; Hekman et al., 2014). In addition, observational
behavior studies often rely on feedback from owners. However, owner ratings have been shown
to be susceptible to pre-existing beliefs and the placebo effect (Gruen, Roe, Griffith, & Sherman,
2017), thus clouding the ability to gauge true efficacy.
Glucocorticoid levels are a common welfare measure, but chronic stress causes
dysregulation of the HPA axis, so glucocorticoid measures can become difficult to interpret
(Hennessy et al., 1997; Hennessy, 2013). Social and spatial restriction has been shown to
increase cortisol levels, increase HPA activity, and over time to decrease HPA responsiveness
(Beerda, Schilder, Bernadina, van Hooff, de Vries, & Mol, 1999a; Hennessy et al., 1998).
Cortisol levels are routinely found to be elevated in shelter settings, with plasma adrenocorticoid
levels found to be raised after as little as 4 hours in a novel environment (Hennessy et al., 1997).
Cortisol is increased over the first three days in a shelter setting, and this increase is three times
higher than the cortisol level of a dog in their own home. Levels appear to begin to drop after day
three (Coppola et al., 2006; Hennessy, 2013; Hennessy et al., 1997; Protopopova, 2016;
Shiverdecker et al., 2013). While heavily represented in the studies reviewed here, cortisol poses
problems as a measure of welfare (Beerda et al., 1999a; Coppola et al., 2006; Hekman et al.,
2014; Hennessy, 2013; Hennessy et al., 1997; Hilby et al., 2006; Protopopova, 2016;
Shiverdecker et al., 2013). Collection methods are often intrusive if not also invasive, and the
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collection method itself can artificially influence the level. Cortisol is not specific to welfare or
stress, but rather is produced during sustained physical and/or psychological arousal (Hekman et
al., 2014; Hilby et al., 2006). Cortisol also shows a high level of variation both between
individuals and within an individual (Hekman et al., 2014).
Despite millions of dogs entering shelters each year, canine welfare and stress studies
tend toward case studies and small data sets. Five studies looking at anxiety levels as a result of
specific stimuli and/or as a result of intervention between 1998 and 2017 had subject group sizes
ranging from 10 to 120 dogs. Some studies looked at dogs in animal shelters, and others used
owned dogs in veterinary hospitals (Beerda et al., 1998; Hilby et al., 2006; Gruen et al., 2017;
Gruen & Sherman, 2008; Gilbert-Gregory et al., 2016). Frequently, dogs displaying the potential
to aggress towards a human, dogs who were overtly fearful, and dogs from certain breeds with a
reputation for aggression have been eliminated from study pools (Hennessy et al., 1997). While
human safety is – and should always be – of utmost concern, removing dogs with these typically
fear-based behaviors eliminates an important population within an average animal shelter, likely
representing those with the poorest welfare.
Shelters have been actively trying to ameliorate this stress over recent decades. Following
in the footsteps of zoological societies by recognizing the need for confined animals to have
enriched environments and the ability to practice natural behaviors (Wells, 2004), shelters have
been implementing enrichment that appeals to the different senses – food items, toys, conspecific
social time, exciting and relaxing smells, music, and human interaction (Wells, 2004). While
these enhancements have improved welfare overall, studies have not always found a robust
response to these enrichment types. Toys are a common addition to the kennel, thought to
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encourage curiosity, comfort, and play behavior. However, studies are, at best, split on the effect.
Some indicate that toys can positively influence behavior and increase activity but others find
that dogs in shelter settings show limited interest in toys, having no impact aside from possibly
making the kennel appear more inviting to human visitors (Protopopova & Gunter, 2017; Wells,
2004; Wells & Hepper, 2000). Adult dogs have also been found to habituate quickly to toys. To
be effective they require continuous rotation (Wells, 2004). Therefore, auditory and olfactory
forms of enrichment hold promise. Lavender, chamomile, and synthetic dog-appeasing
pheromone (DAP) have been found to have a positive effect on behavior in shelter, as has
classical music (Wells, 2004). However, additional research is needed to address the impact of
these types of enrichments (Hennessy, 2013). Overall, environmental enrichment appears to be
of value, but a value that is not yet reliably or consistently quantifiable. An enrichment program
also requires significant human effort, time, and attention, and is at the mercy of a shelter’s
available resources.
Pharmacologic interventions have been suggested as a way to improve wellbeing and
decrease stress, particularly when other enrichment and socialization programs have already been
instituted. Studies have pointed out the need for a fast-acting oral anxiolytic that can alleviate the
stress itself and protect mental wellbeing, rather than just diminishing the physical signs of
stress, when dogs are hospitalized or otherwise confined (Gilbert-Gregory et al., 2016; Hekman
et al., 2014). Moderating the initial stress response may help prevent the risk of chronic stress
activation and system dysregulation (Hennessy 2013). Further exploration is needed to determine
how viable this intervention may be and which medications may fill the role, but one that is
appearing with some frequency in veterinary settings is trazodone hydrochloride (trazodone).

TRAZODONE FOR TRANSITION PERIOD INTO AN ANIMAL SHELTER

11

Trazodone is an atypical antidepressant that has been used in human medicine since 1966
(Gruen et al., 2017; Gruen & Sherman, 2008). Atypical antidepressants are multi-modal,
showing multiple mechanisms of action (Betti, Palego, & Giannaccini, 2018). Classified as a
serotonin receptor antagonist and reuptake inhibitor (SARI), trazodone is primarily a serotonin
2A postsynaptic receptor antagonist, and secondarily a presynaptic serotonin reuptake inhibitor
(Ciribassi & Ballantyne, 2014; Gruen & Sherman, 2008). At lower doses it acts with its primary
mechanism of action only; at higher doses, the secondary mechanism is added (Gruen et al.,
2017). The exact dosage breakpoint for this mechanism change in dogs is not yet precisely
known (Gruen et al., 2017). In humans, trazodone is used to treat major depressive disorder
(MDD), which has symptoms including depression, lethargy, disturbed sleep or appetite, and
reduced concentration (Fagiolini, Comandini, Dell’Osso, & Kasper, 2012; Zhang et al., 2014).
Trazodone is also used in veterinary medicine, indicated to treat anxiety and stress and to induce
calm behavior in dogs and cats (Gruen et al., 2017). Trazodone has a high bioavailability with
oral dosing, a wide dose range, is well tolerated, and has few side effects (Gruen et al., 2017;
Gruen & Sherman, 2008). Published dosage ranges for oral administration are 1.7 to 19.5 mg/kg
daily, dosed every 8 to 24 hours, or 2 to 10 mg/kg up to every 8 hours when dosed ‘as needed’
(Ciribassi & Ballantyne, 2014; Gilbert-Gregory et al., 2016). Daily trazodone is commonly used
in dogs diagnosed with generalized anxiety disorders, while ‘as needed’ usage is for dogs
experiencing intermittent anxiety or who have a clear anxiety trigger (ex. thunderstorm phobia)
(Gruen & Sherman, 2008).
There are no studies known to this researcher that have been published or even planned
on the effect of trazodone administration at the time of intake to a shelter to mitigate stress and
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decrease illness rates. There is considerable support for such investigation thanks to anecdotal
success stories, yet only two scientific studies on the effect of trazodone as a single agent have
been conducted and thus far, results are inconclusive at best. A 2016 study of dogs, also in a
veterinary hospital setting, found a reduction in some frenetic stress-related behaviors (lip
licking, panting, and whining), but not in freeze or fractious behaviors (Gilbert-Gregory et al.,
2016). A 2017 study looked at trazodone’s ability to maintain calm behavior in dogs
postoperatively; no significant difference was found in its efficacy against a placebo (Gruen et
al., 2017).
In 2018, Animal Care Centers of NYC (ACC), a New York City animal shelter,
embarked on a pilot study utilizing trazodone as an anti-anxiety medication to ease the transition
period into the shelter environment. This is a jarring transition for most dogs where everything
they were comfortable with and in control of is removed and novelty is ubiquitous. Careful
review of medical and shelter operations policies and procedures have taken place over recent
years to reduce illness levels and increase adoption rates at ACC. Dogs diagnosed with a
contagious respiratory illness, categorized at ACC as canine infectious respiratory disease
complex (CIRDC) and commonly referred to as “kennel cough,” are given a veterinary
examination and antibiotics, and moved to an isolated room away from apparently healthy dogs,
where handlers wear personal protective equipment (disposable gowns, gloves, and shoe covers)
during interactions. All kennels for all dogs are cleaned daily with Rescue® disinfectant cleaner
(https://rescuedisinfectants.com/), healthy dogs cleaned before sick dogs. In spite of these careful
steps, contagious illness remains high, likely due to increased stressors on the immune system in
combination with the presence of an increased viral load and exposure to novel germs.
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ACC has a large staff behavior team focused on providing in-kennel enrichment and outof-kennel socialization and playgroup sessions to keep dogs as engaged as possible during their
time in care. The enrichment program includes walks, conspecific playgroups, individual
socialization sessions, basic cue training, clicker training, classical music playing throughout the
kennel rooms, quiet lights out time overnight, scent enrichment (lavender, DAP, predator and
prey urine), food enrichment (food puzzles, ice blocks, hollow items stuffed with food and
frozen), long lasting chews (bones, cow and pigs’ ears, bully sticks, rawhides), and toys.
In their continued mission to further increase placement rates and reduce illness, having
already addressed the simpler and more obvious obstacles, ACC began looking to
pharmacological interventions. In 2018, ACC’s Senior Director of Veterinary Services, after
discussion with other prominent shelter veterinarians and researchers, decided to pilot the
administration of trazodone doses at the time of intake. Trazodone is commonly used in shelter
settings for stress relief, though its typical use is long-term for dogs who begin showing signs of
kennel stress and behavioral deterioration after being housed in a kennel environment for a
period of time.
The objective behind the current study is to evaluate the impact of trazodone
hydrochloride administered over the first 48 hours of a dog’s arrival at a large municipal animal
shelter in New York City. For shelters like ACC who have made great strides in addressing
overall welfare practices and have attended to the clearest, easiest, and most direct sources of
contagion in a shelter, pharmacological intervention is a logical next step to reduce illness rates
and stress levels.
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Hypotheses
Based upon ACC’s designed and conducted pilot study, it was hypothesized that:
1. The administration of trazodone to dogs during the transition period would result in a
decreased number of dogs diagnosed with CIRDC during their stays.
2. The administration of trazodone to dogs during the transition period would result in a
decreased average length of stay.
3. The administration of trazodone to dogs during the transition period would result in
increased placement and decreased euthanasia outcomes.

Method
Participants: Species. Domestic dogs, Canis lupus familiaris. The sample was determined by
the population of dogs in the shelter during the designated months. All breeds and breed mixes,
ages, and sexes were included. A total of 2,734 dogs’ records were reviewed, and 1,774 dogs’
records were included in the final analysis. Of these 1,774 records, the 2016/2017 baseline
includes 1,364 total dogs and 560 sick dogs, and the 2018 trial of dogs receiving trazodone
includes 410 total dogs and 119 sick dogs.
Facilities: Animal Care Centers of NYC (ACC). ACC is New York City’s only open
admission animal shelter, a combination municipal shelter with a city contract and 501(c)(3)
non-profit that offers a range of community services including pet intake, stray intake, bite
quarantine, legal hold, surrender prevention, owner requested euthanasia, community pet clinics,
field pickups and emergency calls, and adoption, along with foster and volunteer programs. ACC
has two large full-service care centers (in Manhattan and Brooklyn), one small full-service care
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center (Staten Island), two resource centers (Bronx and Queens), and an administrative
headquarters in downtown Manhattan. Each full-service care center has a medical team to care
for all resident animals, and all dogs are given veterinary examinations, parasite control,
vaccinations, microchips, and spay or neuter surgery during their stay. ACC houses and adopts
out dogs, cats, and rabbits, but accepts any animal of any species, behavior, and medical
condition. ACC is contracted to take in animals from all five boroughs. ACC’s 2018 total intake
was 23,095 animals; 2017 intake was 23,501 and in 2016 intake was 29,536. ACC’s 2018
placement rate (sometimes referred to as “live release rate”) was 92.5% (from ACC’s January
23, 2019 Board Meeting Presentation,
https://www.nycacc.org/sites/default/files/pdfs/boardmeetings/ACC%20Board%20Presentation
%20Jan%2023%202019.pdf). ACC has a stated mission of ending animal homelessness in NYC.
All dogs were housed per ACC practices and policies. Dogs are housed individually in
metal Shor-Line kennels of varying sizes. When space allows, all dogs are given double kennel
housing by opening transfer doors between kennels. In this arrangement, dogs are given their
beds (typically Kuranda beds with a blanket on top) and their food and water bowls on one side,
with the other side left open for moving around and eliminating. When space does not allow,
transfer doors are closed as needed and dogs given only a single kennel side with a bed and
food/water bowls. Meals are fed twice daily, at 6am and 6pm. Toys and other in-kennel
enrichment are provided. Dogs are walked throughout the day by staff and volunteers; frequency
and duration of walks is based on each dog’s individual needs and behaviors. This study did not
request any changes made to any dog’s housing, treatments, enrichment, or movements through
the shelter.
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Procedures
The trazodone pilot began in June 2018, during which time the experimental group
received the pharmacological intervention of trazodone. In years 2016 and 2017 no trazodone
was administered and thus served as a pre-trazodone baseline. All dogs received two doses of
trazodone during their transition period into the shelter, determined to be the first 48 hours in the
new location. All trazodone doses used during this trial were prescribed by licensed veterinarians
at 5mg/kg by mouth, the first dose given by the medical team as close to a dog’s arrival as
possible, and a second dose given the following morning (source: ACC Internal Memorandum).
The decision was made to include only dogs with lengths of stay of four or more days in the final
data set. Analyzing exclusively the data of dogs in the shelter for more than three days allowed
us to focus on the period immediately following that transition period to evaluate effect. We did
not feel we could adequately evaluate effect on dogs who were in care for a shorter period, so
their inclusion would have distracted from the focus of the study by impacting average lengths of
stay and illness rates.
Data on the pilot’s procedural success (dates trazodone given, illness and outcome rates)
were collected in June, July, and August 2018 when the trazodone was initially introduced, but
no data from these months are included in this study because this time was used to streamline the
implementation of the trazodone policy and to evaluate the data collection process. November
and December were selected as the months to be evaluated each year.
Intake spreadsheets were created by running intake reports in either the Chameleon
(2016) or the Shelter Buddy (2017 and 2018) database. The databases contained the same
essential information for each animal, but in October 2017 ACC changed its record-keeping
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system from the former to the latter. Reports included all dogs who came directly into the
Brooklyn and the Manhattan Care Centers from November 1 through December 31 for each of
the three years, live intakes only, from all sources, all intake reasons, and all jurisdictions. Each
list was exported to Excel and the data sorted by intake date. For situations involving repeated
stays in the care center, first stays were included and subsequent stays excluded if the dog was
out of the care center for less than 20 full days. This amount of time allowed for the development
and treatment of CIRDC should it appear and/or reappear post-adoption. Dogs diagnosed with
CIRDC in-shelter remained available for adoption per ACC protocols, and after diagnosis sick
dogs were often added to ACC’s “at risk list,” which may or may not facilitate a more urgent
placement.
For all dogs meeting the inclusion criteria, each dog’s name, unique identification
number, intake date, behavior assessment determination, CIRDC diagnosis date, outcome type,
and exit date was pulled from the database and recorded on the Excel spreadsheet. Outcome
types include public adoption (“adopted”), placement with a rescue group partner (“placed”),
movement into an ACC foster home (“foster”), reunification with the owner (“reclaimed”), and
euthanasia for medical and/or behavioral reasons (“euthanized”). Additionally, for November
and December 2018, the dates of the first and second trazodone doses were recorded for each
dog. Cleaning the collected data produced the final data sets (see Table 1). The data from these
final data sets were used to calculate the total number of dogs tracked for each month in each
location, total number diagnosed with CIRDC, average length of stay, and outcome.
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Table 1
Final Group Sizes
Year

Month

Shelter location

Total records
reviewed

Final sample
size (all)

Final sample
size (sick)

2016

November

Brooklyn Care Center

186

133

65

2016

November

Manhattan Care Center

289

197

81

2016

December

Brooklyn Care Center

261

204

98

2016

December

Manhattan Care Center

296

217

80

2017

November

Brooklyn Care Center

210

147

51

2017

November

Manhattan Care Center

206

145

65

2017

December

Brooklyn Care Center

224

159

50

2017

December

Manhattan Care Center

224

162

70

2018

November

Brooklyn Care Center

216

91

30

2018

November

Manhattan Care Center

223

111

33

2018

December

Brooklyn Care Center

170

86

22

2018

December

Manhattan Care Center

229

122

34

Data Analysis
Data sets were created using Microsoft Excel and data were analyzed with IBM SPSS 25.
Pearson chi-square tests were run for the count data and an independent samples t-test (twotailed) was run for the data looking at averages. The assumptions of independent observations,
normality, and homogeneity were met for the parametric t-test. The alpha level was .05, but in
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cases of multiple comparisons a Bonferroni correction was used to reduce the risk of type 1
error. This correction decreased the alpha level to .01.

Results
Trazodone Dosing
For the trazodone pilot months of November and December 2018, the ideal scenario
followed the protocol as determined by the senior medical director: first dose on the day of
intake, second dose the following morning. However, due to the real world constraints of an
active shelter, not all dogs coming into the care center received doses on this schedule. Exam
delays caused some dogs to receive their first doses on their second or even third day in the care
center. Additionally, some dogs did not receive or consume a second trazodone dose. Multiple
types of high-value treats and foods were used to encourage consumption, but if the dog did not
eat their second dose this was recorded as a missed dose. Ultimately the decision was made to
consider three different dosing scenarios: ideal (as per protocol); dogs with a delayed first dose
but who still received two doses within 48 hours of arriving at the shelter; and dogs who received
one dose on day one in the shelter but did not receive or refused to eat a second dose. See Table
2 for the descriptive data. A Pearson chi-square test run to compare the three schedules found no
significant difference amongst the different methods of dosing, ꭓ2, (2, N = 410) = .49, p = .784.
Therefore, all three of these schedules were included in the trazodone pilot data set.
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Table 2
Final Descriptive Data for Trazodone Dosing Schedules
2018

Sick

Not sick

Total

Percent sick

Ideal, 2 doses

69

158

227

30.40

Delayed, 2 doses

16

41

57

28.07

1 dose on day 1

34

92

126

26.98

Illness Rate
To evaluate whether a significant difference in illness rate existed between the Manhattan
and Brooklyn shelters in the baseline years (2016/2017) compared to 2018, a Pearson chi-square
test was conducted. No significant difference was observed, ꭓ2 (1, N = 1774) = 2.0, p = .16.
Therefore, data for the two shelters were combined as a baseline.
To evaluate whether a significant change in illness rate occurred in the baseline years
(2016/2017) compared to the trazodone pilot (2018), a Pearson chi-square test was conducted.
Table 3 includes group sizes for the baseline and trazodone years. A significant drop in illness
rates during the trazodone trial was observed, ꭓ2 (1, N = 1774) = 19.3, p < .000. The average rate
of illness in the baseline years was 41.1%; during 2018, when the trazodone administration was
introduced, illness rate dropped to 29%.
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Table 3
Group Sizes for Baseline and Pilot
Years

Baseline

Number

Number

Total

Percentage

Sick

Not sick

560

804

1364

41.1

119

291

410

29.02

Sick

2016/2017
Trazodone pilot
2018

Length of Stay
To evaluate changes in length of stay, the baseline years were compared to 2018 (using
the descriptive data presented in Table 2). An independent samples t-test (two-tailed) was
conducted. Equal variances could be assumed. Results indicate that dogs in the shelter during the
baseline years had a longer average length of stay (M = 10.47, SD =8.52) than did those in the
shelter during the trazodone pilot year (M = 9.22, SD = 6.56). Therefore, dogs receiving
trazodone had a significantly shorter average length of stay, t(1772) = 2.75, p = .006. Further
analysis was done by looking at the sick and non-sick samples individually. A t-test was
conducted using the samples of dogs not diagnosed with CIRDC (non-sick) during the baseline
years and trazodone year, and found no significant difference between the baseline year (M =
8.29, SD = 8.13) and the trazodone year (M = 7.75, SD = 6.00), t(1093) = 1.037, p = .300. For the
sample of sick dogs only, a t-test could not be run because the data violated the equal variance
assumption. Therefore a non-parametric Mann-Whitney test was run. This test also found no
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significant difference between baseline 2016/2017 and trazodone 2018 (U = 31325.5, Z = -1.028,
p = .304).
Outcome
To evaluate differences in outcome between the baseline and trazodone pilot years, a
Pearson chi-square was conducted. A statistically significant difference was observed within the
five outcome groups between 2016/2017 and 2018, ꭓ2, (4, N = 1774) = 24.2, p < .000 (see Table
4 for descriptive data). In order to determine where the significant difference occurred, the three
years were compared individually by Pearson chi-square using a Bonferroni correction (p = .01)
to reduce the risk of type 1 error.
Table 4
Outcome Data for Baseline and Pilot
Outcome

Baseline 2016/2017
Number

Percent

Trazodone pilot 2018
Number

Percent

Total number
Number

Percent

Adopted

416

30.5

172

42.0

588

33.1

Placed

648

47.5

175

42.7

823

46.4

Reclaimed

122

8.9

27

6.6

149

8.4

Foster

35

2.6

2

0.5

37

2.1

Euthanized

143

10.5

34

8.3

177

10.0

Total

1364

410

1774

A statistically significant difference was observed in adoption outcomes between the
baseline years 2016/2017 and trazodone pilot 2018, ꭓ2, (1, N = 1774) = 18.7, p < .000. The
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average adoption rate for 2016/2017 was 30.5%, which increased to 42% in 2018. No significant
difference was observed in average rates of euthanasia ꭓ2, (1, N = 1774) = 1.7, p = .19,
placement ꭓ2, (1, N = 1774) = 2.6, p = .07, reclaim ꭓ2, (1, N = 1774) = 2.3, p = .13, and foster
outcomes ꭓ2, (1, N = 1774) = 6.7, p = .010.

Discussion
All three hypotheses put forth at the start of this study were supported by the data
(although the third hypothesis was only partially supported). The first hypothesis suggested that
the administration of trazodone to dogs during the transition period would result in a decreased
number of dogs diagnosed with CIRDC during their stays. The data supported this hypothesis,
finding a statistically significant decrease in the number of dogs diagnosed in 2018 during
trazodone administration versus 2016 and 2017. This means that dogs receiving trazodone had a
lower incidence of contagious illness than did dogs not receiving the pharmacological
intervention. As this one was one of main goals of the pilot from the veterinary perspective, this
is a welcome and meaningful result.
Hypothesis two stated that the administration of trazodone to dogs during the transition
period would result in a decreased average length of stay. This was also supported by the
finding that there was a statistically decreased length of stay from the baseline years to the
trazodone pilot year, meaning dogs left the shelter more quickly, on average, in 2018 than they
had in 2016 and 2017. Strangely, we did not see significant differences in length of stay when we
look at the sick and non-sick populations individually. Practically speaking, becoming sick may
increase LOS for dogs if adopters are wary of taking in a sick dog, while decreasing LOS in
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other cases through placement on ACC’s at risk list with its new venue of visibility. However, it
is possible that these results, specifically the different in LOS, further represent the successful
effects of the trazodone administration. Since all dogs were given trazodone in 2018, it may be
the case that LOS was shortened for this group overall because dogs were less likely to become
sick. Length of stay for dogs with CIRDC is likely to remain consistent across the conditions,
regardless of the use of trazodone, given that it is not an antibiotic. Thus, this non-significant
difference within the sick and non-sick populations may not be so surprising. These results,
however, require additional exploration and further study.
Finally, the third hypothesis predicted that the administration of trazodone to dogs during
the transition period would result in increased placement and decreased euthanasia outcomes.
Of the five outcome types studied, a significant difference between baseline and pilot years was
found in only one: adoption. Therefore the hypothesis was partially supported: this one outcome
(adoption) is related to increased placement, so the dogs receiving trazodone experienced an
increased rate of adoption; however, the pilot appeared to have no measurable effect on overall
euthanasia rates, so the prediction of decreased euthanasia outcomes was not found. This does
not mean that euthanasia remained consistent in all categories. Euthanasia at ACC occurs for a
number of reasons, both medical and behavioral, and it is possible that euthanasia of dogs for
contagious medical illness (CIRDC) decreased while euthanasia for behavioral reasons
increased, keeping overall numbers fairly consistent but reducing euthanasia in behaviorally
sound, medically treatable animals. This study is unable to evaluate the data in such a way, but
perhaps future research can look more deeply at specific outcomes to consider such a possibility.
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As this is the first known exploration of trazodone administration at the time of intake
into an animal shelter, these results open a door for future exploration. The primary goal of
ACC’s pilot program was to decrease the incidence of contagious illness in the shelter, and while
the results here certainly do not indicate causation, they do suggest that a trazodone intervention
during this difficult transition period can be an asset in accomplishing this goal. This study is
also distinguished from many other canine studies in the sheer number of dogs included (1,774)
as compared to the 120 or fewer included in similar studies. This study involved the full
population of the shelter during the months evaluated, with no dogs excluded for breed, age,
behavior, or medical reasons, making the sample representative of the true, complete shelter
population in New York City. This study also required no changes to be made to the dogs’
schedules and quality of care during their stay, so we were able to evaluate dogs as they
experienced typical shelter life.
While trazodone has a history of being used long-term for management of generalized
anxiety disorders (Ciribassi & Ballantyne, 2014), the results of this study indicate a possible
practical new use. Previous studies have acknowledged that intervention within the first days in a
shelter is critical for a dog’s success (Hennessy et al., 1997). Therefore, the more options
available for trial during this time may ultimately result in increased observable success. The
hope (and expectation) was that trazodone would moderate stress, thereby preventing the
suppression of the immune system and decreasing rates of illness. The results of this study
support the possibility that trazodone can assist in this way. In light of this promising first study,
these results should encourage further study in the area of trazodone as a short-term moderator of
transitional stress.
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Limitations. This real-world study took place in an active, full-service shelter and,
therefore, is subject to the restrictions and challenges of being one small piece of a great number
of activities and focuses throughout the day. While the aim was to give all dogs a first dose
immediately following intake and a second dose eight to 24 hours later, this schedule was not
always practical. Delayed intake exams resulted in delayed first doses in some cases, and a
considerable number of dogs refused to eat a second dose the following morning. However, this
ended up allowing for an additional comparison that was not initially planned: looking at
differences amongst different trazodone administration schedules. Ultimately, we included dogs
who had received two doses within the 48-hour transition period, comprising a group that
followed the ideal schedule and a group with a delayed first dose; and dogs who had received
their first dose at intake but who, for any number of reasons, did not receive a second dose. A
comparison of these schedules revealed no significant differences, so it is possible that the same
effect may be found from a single trazodone dose at intake and subsequent doses may not be
necessary. This idea merits additional study to determine an ideal dosing schedule, perhaps with
larger numbers in each group (the smallest number in the trazodone comparison groups was 16,
the largest 158) for a more robust comparison. Should a single dose prove to be effective, it will
make trazodone an even easier and more cost-effective intervention. Should further study
confirm these findings, trazodone becomes a truly viable option for many animal shelters to
address the ongoing concern of transitional stress. At a cost of approximately nine cents per
100mg pill, it falls within a range of budgets, and as it is administered orally it requires relatively
few resources. Even the most purpose-built, well-designed and well-staffed animal shelters
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present a range of uncontrollable stressors to dogs, so the scope of benefit for this intervention is
wide-ranging.
ACC’s policies, procedures, and facilities are continually changing in line with emerging
best practices and new reports from the welfare industry. While this study was controlled to the
extent possible, a number of changes have occurred that may influence lengths of stay, adoption
rates, and illness rates over the three years surveyed. These include changes in adoption policy
(from closed holding rooms in 2016 to an open building and a pre-adoption policy in 2017),
changes made to kennels (some kennels were replaced and/or altered in early 2017, including a
shift from single kennels to open transfer doors and double kennels for dogs whenever
population allows), changes to feeding times and introduction of an overnight lights-out period
of rest for the dogs in early 2017, removal of breed labels, staffing changes, soft music playing in
the rooms in 2016 and 2018 but not 2017, changes to the enrichment program (more varied and
more frequent in-kennel enrichment as the years progress), and a shift of databases in 2017 from
Chameleon to Shelter Buddy for record-keeping. All diagnoses were made by licensed and
practicing veterinarians, but the medical staff experienced numerous changes from the start to the
end of the study, and diagnoses were made by different veterinarians both within and between
the months evaluated.
This study finds a correlation between the administration of trazodone and decreased
illness rates, decreased LOS, and increased adoption rates, but is unable to suggest causation.
Pains were taken to control what was able to be controlled in such a setting and to create
meaningful comparisons between groups. The data analysis took these limitations into
consideration as well by comparing individual years against one another to further isolate the
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effect of the trazodone. While 2016 and 2017 were ultimately combined to form the baseline
data, all three years were looked at separately in the course of the analysis. Trazodone as the sole
cause for the significantly lower rate of illness in 2018 cannot be claimed from this study;
however, the fact that no difference was found between 2016 and 2017, during which a number
of in-shelter changes to the facility and the practices took place, but a significant difference was
found between 2018 and combined 2016/2017, does make for a stronger argument.
Rather than looking at physiological, chemical, or behavior measures (alone or in
combination), this study evaluated outcome. It therefore presents a means of measure that has not
been explored in depth in previous studies. With the remarkable challenge that measuring animal
welfare entails, and the problems with the different parameters that have been investigated
(Beerda et al., 1998; Hilby et al., 2006; Hekman et al, 2014), additional methods to try and
measure this elusive notion will create new study opportunities.
The decrease in length of stay and increase in adoption rates in 2018 cannot be fully
explained by the results of this study and is likely the outcome of a number of influences.
However, extrapolating from trazodone’s mechanism of action and the results seen during this
study, it is possible that a decrease in stress levels has resulted in improved behavior in the
shelter, better kennel presence and more engaged adoption interactions. This could have an
overall effect of more frequent and faster adoptions and placements, resulting in shorter lengths
of stay. While overall numbers used in this study were large, when broken down by outcome
type some of the groups became significantly smaller (as few as 2), making analysis somewhat
less robust. Overall, though, with a trend toward decreased illness, decreased length of stay, and
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increased adoption in months of trazodone administration, this pilot produced exciting and
promising preliminary results for single agent therapy with trazodone hydrochloride.
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